Oncotelic Therapeutics (OTCQB: OTLC) has introduced an artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company’s proprietary PDAOAI technology with advanced robotics from its partner TechForce Robotics, aiming to help pharmaceutical and biotechnology companies streamline manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
The platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. According to the company, this launch marks a significant step in modernizing pharmaceutical manufacturing, which traditionally relies on manual processes that can be error-prone and inefficient.
Oncotelic also highlighted progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents, underscoring the firm’s innovative capacity.
The launch comes as the pharmaceutical industry increasingly adopts digital solutions to enhance manufacturing efficiency and compliance. Oncotelic’s platform addresses a critical need for integrated AI and automation in GMP environments, which could reduce costs and accelerate time-to-market for new therapies. The company’s collaboration with TechForce Robotics provides specialized automation expertise for pharmaceutical applications.
Oncotelic also owns a 45% stake in GMP Bio, a joint venture that advances additional drug candidates. The PDAOAI platform underpins both the new manufacturing services and the company’s drug discovery and lab automation efforts. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, Oncotelic seeks to provide end-to-end solutions from development to production.
For more details on the press release, visit https://ibn.fm/upnBW. Updates on Oncotelic are available in their newsroom at https://ibn.fm/OTLC.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform at BIO 2026.